August 26, 2010

TGaS Advisors Named to Inc. 5000; Among Top 20 in Philadelphia Area

TGaS® Advisors, a leading benchmarking and advisory services firm for the pharmaceutical industry, has been recognized for the third year in a row as one of America's fastest growing companies in the United States by Inc. magazine in its 2010 rankings.

TGaS Advisors ranks in the Top 20 in the Philadelphia area and the Top 100 nationwide in Business Products & Services. In addition, the firm has also been named best in its local business area in the Pharmaceutical Consultants category by the U.S. Local Business Association (USLBA) for the third year in a row.

Despite the difficult economic climate, TGaS Advisors revenue grew 288% in 2006-2009. The reason is clear, according to Stephen E. Gerard, TGaS Advisors Founder and Managing Partner. "Every functional area in almost every pharmaceutical company is re-examining the way it does business and making changes to meet the demands of the industry's 'new normal,'" he said. "An increasing number of top-tier companies recognize that TGaS can make a difference to their bottom line because we help Commercial Operations leaders become more effective strategic business partners." Gerard and partner Jim Mercante authored a White Paper to underscore this point: "The Five Things We Need to Do to Re-Invent Commercial Operations."

The firm recently launched three new Commercial Operations options — Best of Benchmark, Efficiency Benchmark and Strategic Priorities Benchmark – building on the peer-to-peer benchmark methodology that has made TGaS Advisors the leading source of fact-based advice in the pharmaceutical industry. Also in 2010, the firm strengthened its offerings in Digital & Relationship Marketing,[Managed Markets, PDMA Compliance and Training & Development. An advisory benchmark evaluating the "New" Commercial Model in pharma will be announced in the coming months. This benchmark will separate myth from reality regarding changes to the pharmaceutical commercial model.

Another aspect of the firm's success is its "Trusted Advisor" approach. Most TGaS Advisors associates are 20-year industry veterans, coming to the firm from such companies as Wyeth, Roche Pharmaceuticals, Schering-Plough, King Pharmaceuticals, Abbott Laboratories, Yamanouchi (Astellas), Thomson Reuters, IMS Health and SimStar (Rosetta Interactive).

About the Inc. 500/5000

The 2010 Inc. 500/5000 is ranked according to percentage revenue growth when comparing 2006 to 2009. To qualify, companies must have been founded and generating revenue by June 30, 2006. Additionally, they had to be based in the United States, privately held, for profit and independent – not subsidiaries or divisions of other companies – as of December 31, 2009. The minimum revenue required for 2006 is $80,000; the minimum for 2009 is $2 million. The top 10 percent of companies on the list constitute the Inc. 500, now in its 29th year.

About TGaS Advisors

Ranked in the top 100 among U.S. Business Products & Services companies by the Inc. 500, TGaS Advisors is the leading benchmarking and advisory services firm serving pharmaceutical commercial operations organizations. The TGaS Advisors roster includes the top 10 and the majority of the top 50 pharmaceutical companies with operations in the U.S. market. The firm provides the only comprehensive series of benchmarking solutions and advisory services for objectively improving the strategy and effectiveness of pharmaceutical operations organizations. TGaS Advisors is based in East Norriton, Pennsylvania.

Contact: Susan Youdovin for TGaS Advisors; 973-715-6570